QuantuMDx and Menarini Announced an Agreement for the Distribution of the Q-POCTM Platform
On November 2, 2022, QuantuMDx Group Limited, a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), announced an exclusive distribution agreement for QuantuMDx’s Q-POC™ platform in UK and France.
As per the terms of the contract, QuantuMDx's SARS-CoV-2 assay, Q-POCTM, and its new SARS-CoV-2, Flu A/B, and RSV Respiratory Panel test, which the Company launched earlier this year, will all be marketed, sold, and serviced by Menarini. Initial distribution to the UK and France will be covered by the fiv...
